Tibulizumab Dose A

Phase 2

Tibulizumab Dose A is one of 3 therapeutic programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hidradenitis Suppurativa (HS)Active, not recruiting

Hidradenitis Suppurativa (HS)Phase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Hidradenitis Suppurativa (HS)

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Approved

1 2

Povorcitinib

Incyte

Phase 3

2 3

Tibulizumab Dose A

ZZura Bio Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Hidradenitis Suppurativa (HS)

NCT06993610

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa

Active, not recruiting·ZZura Bio Inc·Phase 2·NCT06993610·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tibulizumab Dose A. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tibulizumab Dose A. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zura Bio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: ZZura Bio Inc

Tibulizumab Dose A

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

References

Drug Info

Quick Facts

Related News